CHIP

Five ways Trump’s efforts to strip the ACA will affect healthcareHere’s a quick guide to the meaning behind Trump’s executive order and decision to stop cost-sharing reduction payments.
How Trump will change four major healthcare programs, initiativesThe ACA, Medicare, Medicaid, the Children’s Health Insurance Program, and prescription drugs are in the sights of many who will soon be running Washington.
MACRA changes physician reimbursement modelThe new “MACRA” system, underway as of January 2017, massively changes the way physicians are paid under Medicare and will impact pediatricians indirectly but substantially, say experts.
Trump nominates new leader for CMSPresident-elect Donald Trump has announced he will nominate Seema Verma, MPH, a consultant with extensive work in Medicaid in several states, to lead the Centers for Medicare and Medicaid Services (CMS).
Red state, blue state: What the election may mean for kids
Red state, blue state: What the election may mean for kidsOne candidate favors reducing the government’s role in healthcare, the other increasing it. One candidate offers broad-brush proposals, the other detailed policy briefs. One candidate has spent years working on children’s welfare, the other has no public track record on it.
MACRA author calls for delay in reporting requirements
MACRA author calls for delay in reporting requirementsPhysicians won’t have to start reporting quality under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) until next July at the earliest, if the law’s co-author has his way.
Opinion: 6 ways to modernize federal health data policyCreating a national data policy framework for empowered consumer choices.
MACRA final rule could hit healthcare industry hardMACRA, which will further the shift to value-based reimbursement, has industry insiders grappling with the complexities, particularly those related to reporting guidelines for providers.
Pharma industry must adopt value-driven perspective: Providers and health plans aren’t the only industry groups affected by the shift to value-based care. It’s time for pharma to get in on the action.
New CMS rule could significantly impact Medicaid managed careCMS regulation will lead to major changes in Medicaid managed care programs; changes that focus on quality improvements, increased transparency and accountability, and strengthened state and federal oversight.